Cover Image
Read Now

Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

The current CADTH Common Drug Review (CDR) submission for ocrelizumab is for use in the treatment of patients with primary progressive MS (PPMS). CADTH has previously reviewed ocrelizumab for use in the treatment of adult patients with relapsing remitting MS (RRMS)

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, May 2018
Series:CADTH common drug review
Subjects:
Multiple Sclerosis, Chronic Progressive / Drug Therapy
Antibodies, Monoclonal, Humanized / Adverse Effects
Treatment Outcome
Antibodies, Monoclonal, Humanized / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The current CADTH Common Drug Review (CDR) submission for ocrelizumab is for use in the treatment of patients with primary progressive MS (PPMS). CADTH has previously reviewed ocrelizumab for use in the treatment of adult patients with relapsing remitting MS (RRMS)
Item Description:"Version: Final."
Physical Description:1 PDF file (89 pages) illustrations

Similar Items